Carillon Tower Advisers’s Tandem Diabetes Care TNDM Stock Holding History

Carillon Tower Advisers’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$29.4M	Sell	306,933 -4,962	-2%	-$511K	0.18%	174
2020 Q3	$35.4M	Sell	311,895 -147,020	-32%	-$15.4M	0.47%	50
2020 Q2	$45.4M	Sell	458,915 -303,632	-40%	-$24.2M	0.35%	95
2020 Q1	$46.1M	Buy	762,547 +53,528	+8%	+$3.75M	0.45%	62
2019 Q4	$42.3M	Hold	709,019	–	–	0.28%	127
2019 Q3	$41.8M	Hold	709,019	–	–	0.29%	125
2019 Q2	$45.7M	Sell	709,019 -213,716	-23%	-$13.8M	0.31%	111
2019 Q1	$58.6M	Buy	922,735 +190,728	+26%	+$10M	0.41%	76
2018 Q4	$27.8M	Hold	732,007	–	–	0.24%	168
2018 Q3	$31.4M	Buy	+732,007	New	+$25.6M	0.22%	172

Other funds holding TNDM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Carillon Tower Advisers's TNDM Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Tandem Diabetes Care (TNDM) stake by 1.6% in Q4 2020, selling an estimated $511K and leaving 306,933 shares worth $29.4M. The position accounts for 0.18% of the portfolio, ranked #174.

Carillon Tower Advisers first reported a position in TNDM in Q3 2018 and has held it in 10 quarters since. The position peaked at $58.6M in Q1 2019. 309 funds tracked by Wall St. Rank hold TNDM as of Q4 2020.

Carillon Tower Advisers held 306,933 shares of Tandem Diabetes Care worth $29.4M as of Q4 2020.
Carillon Tower Advisers sold 4,962 Tandem Diabetes Care shares in Q4 2020, an estimated $511K.
Tandem Diabetes Care made up 0.18% of Carillon Tower Advisers's portfolio in Q4 2020, its #174 holding.
Carillon Tower Advisers first reported a position in Tandem Diabetes Care in Q3 2018 and has held it in 10 quarters since.
Carillon Tower Advisers's Tandem Diabetes Care position peaked at $58.6M in Q1 2019.
309 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.